Global Uveitis Drugs Market 2019-2023
SKU ID : TNV-14326682 | Publishing Date : 03-Jun-2019 | No. of pages : 130
Detailed TOC of Global Uveitis Drugs Market 2019-2023
PART 01: EXECUTIVE SUMMARYPART 02: SCOPE OF THE REPORT
2.1 Preface
2.2 Preface
2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
Market ecosystem
Market characteristics
Market segmentation analysis
PART 04: MARKET SIZING
Market definition
Market sizing 2018
Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
Bargaining power of buyers
Bargaining power of suppliers
Threat of new entrants
Threat of substitutes
Threat of rivalry
Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
Market segmentation by product
Comparison by product
Small molecules - Market size and forecast 2018-2023
Biologics - Market size and forecast 2018-2023
Market opportunity by product
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
Geographic segmentation
Geographic comparison
North America - Market size and forecast 2018-2023
Europe - Market size and forecast 2018-2023
Asia - Market size and forecast 2018-2023
ROW - Market size and forecast 2018-2023
Key leading countries
Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
Market drivers
Market challenges
PART 11: MARKET TRENDS
Development of gene therapy
Special designations
Increasing popularity of combination therapies
PART 12: VENDOR LANDSCAPE
Overview
Landscape disruption
Competitive scenario
PART 13: VENDOR ANALYSIS
Vendors covered
Vendor classification
Market positioning of vendors
AbbVie Inc.
Allergan Plc
Johnson & Johnson Services Inc.
Novartis AG
Pfizer Inc.
PART 14: APPENDIX
Research methodology
List of abbreviations
Definition of market positioning of vendors
PART 15: EXPLORE TECHNAVIO
Exhibit 01: Global ophthalmology drugs market
Exhibit 02: Segments of global ophthalmology drugs market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Product - Market share 2018-2023 (%)
Exhibit 18: Comparison by product
Exhibit 19: Small molecules - Market size and forecast 2018-2023 ($ millions)
Exhibit 20: Some of the generic sponsors for corticosteroids
Exhibit 21: Different forms of corticosteroids
Exhibit 22: Small molecules - Year-over-year growth 2019-2023 (%)
Exhibit 23: Biologics - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Some of the biologics used in uveitis
Exhibit 25: Cost of some biologics
Exhibit 26: Some of the approved biosimilars
Exhibit 27: Biologics - Year-over-year growth 2019-2023 (%)
Exhibit 28: Market opportunity by product
Exhibit 29: Customer landscape
Exhibit 30: Market share by geography 2018-2023 (%)
Exhibit 31: Geographic comparison
Exhibit 32: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 33: North America - Year-over-year growth 2019-2023 (%)
Exhibit 34: Top 3 countries in North America
Exhibit 35: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 36: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 37: Top 3 countries in Europe
Exhibit 38: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 39: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 40: Top 3 countries in Asia
Exhibit 41: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 42: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 43: Top 3 countries in ROW
Exhibit 44: Key leading countries
Exhibit 45: Market opportunity
Exhibit 46: Prevalence of associated risk factors for uveitis
Exhibit 47: Drug development pipeline late stage molecules for uveitis
Exhibit 48: Adverse effects associated with available drugs
Exhibit 49: Impact of drivers and challenges
Exhibit 50: Vendor landscape
Exhibit 51: Landscape disruption
Exhibit 52: Vendors covered
Exhibit 53: Vendor classification
Exhibit 54: Market positioning of vendors
Exhibit 55: AbbVie Inc. - Vendor overview
Exhibit 56: AbbVie Inc. - Business segments
Exhibit 57: AbbVie Inc. - Organizational developments
Exhibit 58: AbbVie Inc. - Geographic focus
Exhibit 59: AbbVie Inc. - Key offerings
Exhibit 60: AbbVie Inc. - Key customers
Exhibit 61: Allergan Plc - Vendor overview
Exhibit 62: Allergan Plc - Business segments
Exhibit 63: Allergan Plc - Organizational developments
Exhibit 64: Allergan Plc - Geographic focus
Exhibit 65: Allergan Plc - Segment focus
Exhibit 66: Allergan Plc - Key offerings
Exhibit 67: Allergan Plc - Key customers
Exhibit 68: Johnson & Johnson Services, Inc. - Vendor overview
Exhibit 69: Johnson & Johnson Services, Inc. - Business segments
Exhibit 70: Johnson & Johnson Services, Inc. - Organizational developments
Exhibit 71: Johnson & Johnson Services, Inc. - Geographic focus
Exhibit 72: Johnson & Johnson Services, Inc. - Segment focus
Exhibit 73: Johnson & Johnson Services, Inc. - Key offerings
Exhibit 74: Johnson & Johnson Services, Inc. - Key customers
Exhibit 75: Novartis AG - Vendor overview
Exhibit 76: Novartis AG - Business segments
Exhibit 77: Novartis AG - Organizational developments
Exhibit 78: Novartis AG - Geographic focus
Exhibit 79: Novartis AG - Segment focus
Exhibit 80: Novartis AG - Key offerings
Exhibit 81: Novartis AG - Key customers
Exhibit 82: Pfizer Inc. - Vendor overview
Exhibit 83: Pfizer Inc. - Business segments
Exhibit 84: Pfizer Inc. - Organizational developments
Exhibit 85: Pfizer Inc. - Geographic focus
Exhibit 86: Pfizer Inc. - Segment focus
Exhibit 87: Pfizer Inc. - Key offerings
Exhibit 88: Pfizer Inc. - Key customers
Exhibit 89: Validation techniques employed for market sizing
Exhibit 90: Definition of market positioning of vendors
Keyplayers in Global Uveitis Drugs Market 2019-2023
AbbVie Inc.Allergan Plc
Johnson & Johnson Services Inc.
Novartis AG
Pfizer Inc.